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First Comparison of Hypothermic Oxygenated PErfusion Versus
Static Cold Storage of Human Donation After Cardiac Death
Liver Transplants
An International-matched Case Analysis
Philipp Dutkowski, MD, Wojciech G. Polak, MD, PhD,y Paolo Muiesan, MD,z Andrea Schlegel, MD,
Cornelia J. Verhoeven,y Irene Scalera, MD,z Michelle L. DeOliveira, MD, Philipp Kron, MD, and
Pierre-Alain Clavien, MD, PhD, FACS (Hon)
Background: Exposure of donor liver grafts to prolonged periods of warm
ischemia before procurement causes injuries including intrahepatic cholangi-
opathy, which may lead to graft loss. Due to unavoidable prolonged ischemic
time before procurement in donation after cardiac death (DCD) donation in 1
participating center, each liver graft of this center was pretreated with the new
machine perfusion ‘‘Hypothermic Oxygenated PErfusion’’ (HOPE) in an
attempt to improve graft quality before implantation.
Methods: HOPE-treated DCD livers (n¼ 25) were matched and compared
with normally preserved (static cold preservation) DCD liver grafts (n¼ 50)
from 2 well-established European programs. Criteria for matching included
duration of warm ischemia and key confounders summarized in the balance of
risk score. In a second step, perfused and unperfused DCD livers were
compared with liver grafts from standard brain dead donors (n¼ 50), also
matched to the balance of risk score, serving as baseline controls.
Results: HOPE treatment of DCD livers significantly decreased graft injury
compared with matched cold-stored DCD livers regarding peak alanine-
aminotransferase (1239 vs 2065U/L, P¼ 0.02), intrahepatic cholangiopathy
(0% vs 22%, P¼ 0.015), biliary complications (20% vs 46%, P¼ 0.042), and
1-year graft survival (90% vs 69%, P¼ 0.035). No graft failure due to
intrahepatic cholangiopathy or nonfunction occurred in HOPE-treated livers,
whereas 18% of unperfused DCD livers needed retransplantation. In addition,
HOPE-perfused DCD livers achieved similar results as control donation after
brain death livers in all investigated endpoints.
Conclusions: HOPE seems to offer important benefits in preserving higher-
risk DCD liver grafts.
Keywords: donation after cardiac death, Hypothermic Oxygenated
PErfusion, ischemic cholangiopathy
(Ann Surg 2015;262:764–771)
B efore the introduction of the currently widely accepted braindeath criteria in 1968, donation after cardiac death (DCD) was
the only source of cadaveric grafts for orthotopic liver transplantation
(OLT). Although subsequently in the last 3 decades, donation after
brain death (DBD) has been preferentially used in most countries, the
worldwide increasing shortage of brain death donors reestablished
the interest for DCD donors, as an additional potential pool of organs.
Several reports, however,1,2 suggest inferior graft survival and
increased biliary complications in DCD livers with most concerns
for an ischemic cholangiopathy (IC), typically developing within the
first 3 to 6 months after OLT.1 The majority of transplant physicians
agree that long periods of donor warm ischemia in DCD donation are
responsible for intrahepatic cholangiopathy and graft loss,2–10
besides additional risk factors including donor age,5–7,11 duration
of graft-cold ischemia,4–6 previous liver transplant,4,9 recipient age,9
and recipient body-mass-index.4,12
Dynamic liver preservation techniques, using perfusion of a
variety of solutions at different temperatures, have been proposed to
protect or rescue marginal liver grafts, including DCD livers.13,14 The
Zurich group has developed a hypothermic oxygenated perfusion
system (HOPE) of liver grafts, initially on basis of experimental
research in various animal models,15–21 followed by clinical appli-
cation in grafts obtained from DCD donors earlier this year.22 DCD
donation in Switzerland was possible only at the price of prolonged
normothermic ischemia times due to local legislative regulations, and
justified the routine use of HOPE in an attempt to improve graft
quality before implantation. The aim of the current study is to test the
impact of the HOPE protocol in the first worldwide-perfused 25
human DCD grafts with subsequent transplantation. Thus, we com-
pared standard procurement of DCD grafts, that is, without dynamic
perfusion techniques, with HOPE-treated DCD grafts. Short of a
randomized controlled trial (RCT), we matched both approaches for
the duration of donor warm ischemia and additional key risk factors.
METHODS
Study Design
The study was designed to analyze conventional cold-stored
controlled DCD livers (Maastricht category III) and DCD livers,
treated by HOPE. For this purpose, all HOPE-treated DCD livers
from Zurich (n¼ 25) were matched (1:2) with DCD liver grafts
(n¼ 50) from 2 European DCD liver transplant programs (Rotterdam,
The Netherlands, n¼ 40, and Birmingham, UK, n¼ 10) (Supple-
mentary Table 1, Supplementary Figure 1, http://links.lww.com/
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SLA/A881). The collection of data was approved by the Swiss Cohort
study (KEK-ZH-Nr. 2013-0504). The studyperiodswere January 2012
to December 2014 for HOPE-treated DCD livers, and January 2005 to
January 2014 for unperfused DCD livers.
Criteria for matching included donor warm ischemia and key
confounders summarized in the balance of risk (BAR) score (donor
age, recipient age, model of end-stage liver disease (MELD) score,
cold storage, retransplantation, preoperative recipient life support).23
Matching was performed retrospectively and anonymously using
SPSS software (version 21, IBM Corp, Armonk, NY). Matched
patients were identified by applying hierarchically the following
criteria: primary liver transplant, graft type (controlled DCD), donor
asystolic warm ischemia (cardiac arrest to cold flush) within 4
minutes, and BAR score within 5 points, but below a threshold of
BAR 9, cold storage 8 hours. Matching criteria limits were
extended in the unperfused group for 2 cases with shorter asystolic
warm ischemia (10 and 11 minutes), in 9 cases for cold storage >8
hours, and in 3 of those cases for BAR 10, due to the lack of suitable
matches (Supplementary Table 1, http://links.lww.com/SLA/A881).
The transplant procedurewas performed by classic liver implan-
tation technique in HOPE-treated livers, and by cava preserving
technique (piggyback) in unperfused DCD livers (Rotterdam and
Birmingham). Liver reperfusion was performed in all cases by portal
perfusion first and subsequent arterial perfusion. Bile duct anastomoses
were performed by duct-to-duct technique without stent in most cases.
Hepaticojejunostomywas used in 6% (3/50) of unperfused DCD livers.
The most frequent underlying diseases in recipients were hepatitis C,
alcoholic, or non-alcoholic steatohepatitis cirrhosis (Table 1). Standard
immunosuppression was tacrolimus, azathioprine or mycofenolate
mofetil, and reducing dose steroids. All HOPE-treated patients and
the majority of unperfused DCD recipients (40/50) received additional
basiliximabon day 0 and day 4. The primary endpointwas the incidence
and severity of biliary complications within 1 year after transplantation.
Secondary endpoints included liver ischemia reperfusion injury and
function as well as graft survival.
In a last step, we performed a comparison of HOPE-treated
and unperfused DCD livers with conventional cold-stored DBD
livers, serving as negative controls. For this purpose, 50 liver grafts
from standard brain dead donors from 2 centers (Zurich, n¼ 40, and
Birmingham, n¼ 10) were also matched according to the BAR
score23 (study period February 2004 to May 2014) (Supplementary
Figure 1, http://links.lww.com/SLA/A881).
Key Confounders in Matched Patients
The matching process resulted in comparable asystolic donor
warm ischemia (18 vs 17.5 minutes, ns) and BAR scores (4 vs 5.5, ns)
between DCD groups (HOPE-treated DCD vs unperfused DCD)
(Table 1, Supplementary Figure 1, http://links.lww.com/SLA/A881).
Consistently, donor age and recipient MELD score were also not
different (54 vs 48 years, ns; MELD 13 vs MELD 16, ns) (Table 1).
Significant variations due to less suitable cases seemed in
terms of the following parameters; first, cold storage was generally
shorter in HOPE-treated compared with unperfused livers, because
of in-house donors in all HOPE-treated cases, and also because of
significant reduction of cold ischemia by the length of the perfusion
time (188 vs 395 minutes, P< 0.0001) (Table 1). Secondly, recipient
age was higher in HOPE-treated DCD livers (60 vs 56 years,
P¼ 0.008) (Table 1). Third, despite comparable total donor warm
ischemia time (withdraw to cold flush) in both DCD groups (36 vs 33
minutes, ns), unperfused DCD livers exhibited a shorter period of
relevant hypotension before cardiac arrest, resulting in significant
shorter functional donor warm ischemia (systolic pressure <50mm
Hg to cold flush) in unperfused DCD livers, as compared to HOPE-
treated DCD livers (23 vs 31 minutes, P< 0.0001) (Table 1).
The control group (DBD patients) was comparable with HOPE-
treated and unperfusedDCDpatients in terms ofBARandMELD scores
(Table 1, Supplementary Figure 1, http://links.lww.com/SLA/A881).
Hypothermic Oxygenated Perfusion
Machine perfusion of DCD livers was performed, as reported
earlier.22 Briefly, hypothermic oxygenated perfusion was done in all
cases after cold flush and cold storage during recipient hepatectomy,
exclusively through the portal vein for 1 to 2 hours [median 118
minutes, interquartile range (IQR) 101–149 minutes]. As perfusate,
we used recirculated University of Wiscon-sin (UW) gluconate
solution (KPS-1) at low flow rates (120–180mL/min), which was
TABLE 1. Key Confounders
Unperfused DCD, N¼ 50 HOPE-treated DCD, N¼ 25 DBD, N¼ 50 P 1,2,3
BAR score 5.5 (3–8) 4 (2–4.5) 3.5 (2–6) ns/ns/ns
Donor age 48 y (33–51) 54 y (36–63) 59 y (46–70) 0.0001/ns/0.04
Donor asystolic WI 17.5min (16–20) 18 (17–21) — –/ns/–
Donor functional WI 23min (20–29) 31min (26–36) — –/<0.0001/–
Donor total WI 33min (27–40) 36min (31–40) — –/ns/–
Total preservation time 395min (349–447) 317min (280–391) 350min (286–425) 0.01/0.002/ns
Cold storage (excl. HOPE) 395min (349–447) 188min (141–264) 350min (286–425) 0.01/<0.0001/<0.0001
Recipient age 56 y (49–59) 60 y (57–64) 54 y (50–62) ns/0.0008/ 0.005
Recipient MELD score 16 (10–21) 13 (9–15) 11 (9–17) 0.02/ns/ns
Recipient sex Male 35/50 (70%) Male 20/25 (80%) Male 37/50 (74%) ns/ns/ns
Underlying disease
Alcoholic cirrhosis 15/50 (30%) 4/25 (16%) 5/50 (10%) 0.02/ns/ns
Hepatitis C cirrhosis 11/50 (22%) 8/25 (32%) 19/50 (38%) ns/ns/ns
Hepatitis B cirrhosis 2/50 (4%) 1/25 (4%) 6/50 (12%) ns/ns/ns
Autoimmunhepatitis 4/50 (8%) — — –
Cryptogenic cirrhosis 5/50 (10%) — 9/50 (18%) ns/–/–
PBC 3/50 (6%) 1/25 (4%) 1/50 (2%) ns/ns/ns
PSC 3/50 (6%) 0/25 2/50 (4%) ns/ns/ns
NASH 3/50 (6%) 6/25 (24%) 1/50 (2%) ns/0.05/0.005
Other 4/50 (8%) 5/25 (20%) 7 (14%) ns/ns/ns
Hepatocellular carcinoma 5/50 (10%) 18/25 (72%) 14/50 (28%) 0.04/0.0001/0.0004
MELD indicates model of end-stage liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.

Other underlying diseases: e.g. Polycystic liver disease, Hepatitis of unknown origin or Cholangiocarcinoma.
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oxygenated (pO2 80–100 kPa) and cooled (108C) by an ECOPS
device (Organ Assist).22
Procurement and Definitions
Super rapid en bloc multiorgan retrieval was carried out in all
DCD livers with heparinized flush of abdominal organs by cannu-
lation of the iliac artery after abdominal incision according to earlier
reports.24 No premedication was given to DCD donors before with-
draw of support. The bile duct was flushed in situ and ex situ with
preservation solution. All HOPE-treated DCD liver grafts were
stored after procurement in Institute George Lopez-1 solution until
machine perfusion, whereas unperfused DCD liver grafts were stored
in UW solution. No DCD graft was treated with fibrinolytic agents.
Early allograft dysfunctionwas defined by the occurrence of the
following: bilirubin> 170mmol/L on day 7 after OLT, or international
normalized ratio (INR)> 1.6 on day 7 after OLT, or peak alanine-
aminotransferase (ALT)> 2000U/L within the first 7 days after
OLT.25 IC was defined and classified as either multifocal or unifocal
intrahepatic strictures without the presence of concomitant hepatic
artery thrombosis or arterial complications.1,26 Each patients chartwas
reviewed retrospectively for clinical data, liver function tests, and
imaging. IC was detected clinically and confirmed by images (endo-
scopic, percutaneous, or magnetic resonance cholangiography).
Median follow-up was 448, 528, and 1530 days for HOPE-treated
DCD livers, unperfused DCD livers, and DBD liver, respectively.
Statistical Analysis
The results are expressed in median and IQR for metric
parameters and in percentages for nominal parameters. Continuous
and categorical parameters were compared with the 2-tailed Mann-
Whitney-Wilcoxon nonparametric test; dichotomous parameters
were compared with the Fisher exact test. Survival analysis was
adjusted to cold ischemia in DCD groups (Cox regression). SPSS
version 21 (IBM Corp., Armonk, NY) and GraphPad Prism version 5
(GraphPad Software, Inc, La Jolla, CA) were used for statistical
analysis.
RESULTS
Comparison of HOPE Treated and Unperfused
(Cold-stored) DCD Livers
HOPE treatment of DCD liver grafts improved significantly
several biochemical and clinical parameters during OLT and after 1-
year follow-up (Table 2). First, HOPE-treated DCD livers demon-
strated less liver enzyme release after reperfusion, as compared to
unperfused DCD livers (1239 vs 2065U/L peak ALT, 1808 vs
2848U/L peak aspartate-aminotransferase, 44 vs 109mmol/L peak
bilirubin) (Table 2, Figs. 1 and 2). Secondly, HOPE-treated DCD
livers showed less early allograft dysfunction, as expressed by INR at
day 1 (1.3 vs 1.9, P< 0.0001), or by increase of either ALT, bilirubin,
FIGURE 1. HOPE-treated DCD livers showed significant less need for transfusions (A, B), improved liver graft function (C, F), and
decreased peak liver enzymes (D, E) as compared to unperfused DCD livers. In addition, HOPE-treated DCD livers achieved similar
results as matched DBD livers (A-F).
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or INR during the first week after OLT25 (20% vs 44% early allograft
dysfunction, P¼ 0.046, Table 2). Of note, liver function was delayed
despite significant more substitution of coagulation factors during
OLT in unperfused versus HOPE-treated DCD livers (6 vs 0 U fresh
frozen plasma, Table 2; Fig. 1). Six percent of unperfused DCD liver
grafts (3/50) showed primary nonfunction (PNF) after OLT com-
pared with no PNF in HOPE-treated DCD livers (Table 2). Third,
although HOPE treatment did not decrease the rate of extrahepatic
biliary complications (5/25 vs 12/50), the percentage of intrahepatic
cholangiopathy >1-year follow-up was significantly less compared
with unperfusedDCD livers (0/25vs 11/50,P¼ 0.013; Table 2, Fig. 3).
Consistently, 3- and 6-month serum levels of alkaline phosphates
increased in unperfused as compared to HOPE-treated DCD livers
(Table 2, Fig. 3). Eight of 50 unperfused DCD liver grafts developed
TABLE 2. Outcome After OLT
Unperfused DCD, N¼ 50 HOPE-treated DCD, N¼ 25 DBD, N¼ 50 P1/2/3
Intraoperative RBC 2 U (0.8–6.3) 2 U (0–4) 1.6 U (0–7.3) ns/ns/ns
Intraoperative FFP 6 U (2–12) 0 U (0) 0 U (0–12) 0.01/< 0.0001/ns
Duration of transplant 390min (330–477) 345min (300–413) 350min (300–420) ns/ns/ns
INR day 1 1.9 (1.1–1.6) 1.3 (1.6–2.1) 1.4 (1.2–1.7) <0.0001/<0.0001/ns
Peak ALT 2065 U/L (1331–3596) 1239 U/L (689–2126) 1124 U/L (693–2126) 0.007/0.02/ns
Peak AST 2848 U (1485–6724) 1808 U (1133–3547) 1473 U (762–3764 0.005/0.04/ns
Peak creatinine 158mmol/L (108–218) 154mmol/L (105–313) 159mmol/L (117–248) ns/ns/ns
Renal replacement 5/50 (10%) 7/25 (28%) 11/50 (22%) ns/ns/ns
Peak bilirubine 109mmol/L (60–183) 44mmol/L (21–106) 116 (41–174) ns/0.016/0.046
Early graft dysfunction 22/50 (44%) 5/25 (20%) 11/50 (22%) 0.03/0.046/ns
PNF 3/50 (6%) 0/25 0/50 ns/ns/ns
HAT 3/50 (6%) 1/25 (4%) 1/50 (2%) ns/ns/ns
Acute rejection (>RAI 4) 8/50 (16%) 3/25 (12%) 6/50 (12%) ns/ns/ns
ICU stay 3 d (2–6) 3 d (1.3–5.7) 3 d (2–5.7) ns/ns/ns
Hospital stay 18 d (15–29) 20 d (14–23) 17.5 d (13–26) ns/ns/ns
3-month alkaline phosphatase 178 U/L (77–415) 109.5 U/L (63–740) 100 U/L (79–193) 0.05/0.04/ns
6-month alkaline phosphatase 172.5 U/L (97–327) 92 U/L (71–220) 131 U/L (96.327) ns/0.02/ns
IC 11/50 (22%)
Multifocaly 8/50 (16%) 0/25 2/50 (4%) 0.015/0.013/ns
Unifocaly 3/50 (6%)
Anastomotic strictures or leaks 12/50 (24%) 5/25 (20%) 10/50 (20%) ns/ns/ns
Total biliary complication 23/50 (46%) 5/25 (20%) 12/50 (24%) 0.035/0.042/ns
Retransplant for IC or PNF 9/50 (18%) 0/25 1/50 (2%) 0.031/0.025/ns
Graft loss total 15/50 (30%) 2/25 (8%) 2/50 (4%) 0.009/0.041/ns
1-year graft survival 69% 90% 96% 0.002/0.035/ns
ALT indicates alanine-aminotransferase; AST, aspartate-aminotransferase; FFP, fresh frozen plasma; HAT, hepatic artery thrombosis; ICU, intensive care unit; RAI, rejection
activity index; WI, warm ischemia.

Definition of Early Allograft Dysfunction (EAD) according to Olthoff et al, Liver Transpl. 2010.
25
yDefinition of ischemic cholangiopathy (IC) according to Lee et al, Liver Transpl. 2007 and Buis et al, Liver Transpl. 2007.26,32
FIGURE 2. Cumulative ALT and AST
release during the first week after OLT
demonstrated significant higher reperfu-
sion injury in unperfused DCD livers as
compared to HOPE-treated DCD and
DBD livers (A, B).ALT, alanine-aminotrans-
ferase; AST, aspartate-aminotransferase.
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multifocal ICwith amedian time to retransplantation of 153 days (IQR
75–301 days) (Supplementary Figure 2, http://links.lww.com/SLA/
A881). HOPE treatment resulted furthermore in no graft loss due to
PNF or intrahepatic biliary complications during the observation
period in contrast to 18% graft losses in unperfused DCD livers
(P¼ 0.025, Table 2). Overall and cholangiopathy-free graft survival
after 1 year was 90% inHOPE-treatedDCD livers comparedwith 69%
in unperfused DCD livers (P¼ 0.035; Table 2, Fig. 3). The effect of
HOPE was independent from the length of cold storage as tested by
regression analysis (hazard ratio 4.19; 95% CI, 0.96–18.2).
Comparison of HOPE-treated and Unperfused
(Cold-stored) DCD Livers With DBD Livers
To quantify the effect of HOPE, we compared all DCD livers
with conventional cold-stored DBD livers, matched for key con-
founders by the BAR score.
Although the difference between matched unperfused DCD
livers and DBD livers was high in terms of reperfusion injury, graft
function, later bile duct complications, and graft survival, no
significant differences were observed in all analyzed endpoints
between HOPE-treated DCD livers and matched DBD livers
(Figs. 1–3, Table 2).
DISCUSSION
This is the first comparison between standard-preserved and
HOPE-treated DCD liver transplantation disclosing important
benefits in favor of the HOPE approach. The study shows that
DCD livers treated by HOPE developed less reperfusion injury
and better graft function with a lower incidence of later intrahepatic
biliary complications. The most relevant observation is an improved
graft survival with the use of HOPE. In fact, HOPE-treated DCD
livers achieved similar results in all investigated endpoints compar-
able with low-risk DBD liver transplants.27 The benefits of HOPE
treatment could be documented from the initial phase of reperfusion
until the later follow-up at 1 year after OLT.
FIGURE 3. Parameters of cholestasis (bilirubin, alkaline phosphatase) 3 and 6 months after OLT were significantly less in HOPE-
treated DCD livers as compared to unperfused DCD livers (A-C). Actuarial 1-year graft survival was 90% in HOPE-treated DCD livers
as compared to 69% in unperfused DCD livers (D).
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Randomized trials to compare human machine liver perfusion
techniques with conventional cold storage are not yet available. First
reports on normothermic or hypothermic perfusion are currently
restricted to feasibility and practical aspects in standard or extended
liver grafts.22,28–30 Our recent experimental and clinical observations
have suggested significant advantages for the HOPE technique on
reperfusion injury in DCD livers,18,21 with further downstream
impact on graft immune responses.20 HOPE also conferred protec-
tion against biliary injury in a rodent liver transplant model.19 The
mechanisms seem to be related to changes in mitochondrial respir-
ation rates during HOPE in addition to perfusion effects on the
sinusoidal glycocalix.18,31 It is currently unclear, how much oxygen
is needed under cold perfusion conditions in human livers. We,
however, believe that the effects of HOPE depend on oxygenation of
the perfusate, as recent experimental studies in pig livers with
deoxygenated perfusates point to this fact.18
Due to the severe shortage of organs in Switzerland, a DCD
liver transplant program was initiated in 2012 in Zurich, but with
strict ethical regulations (confirmation of brain death after cardiac
arrest), resulting in long period of asystolic donor warm ischemia.
Due to this unavoidable and unsuitable graft warm ischemia, and the
knowledge gathered in animal models, DCD liver transplants pro-
gram in Zurich included HOPE treatment before implantation.
Candidates for such perfusion approach were selected from the
waiting list in accordance to low BAR score, a long expected waiting
time, and to the presence of hepatocellular carcinoma in most of the
cases (18/25).
Conclusive recommendations must also focus on later biliary
complications occurring within the first year after OLT.1,7,32 Short of
an unperfused DCD liver group in Zurich, we searched for a
comparable group of DCD livers in 2 well-established European
DCD liver transplant centers. To further optimize comparability
between the groups, we choose an anonymously computerized
matching program offering equal distribution of several key
parameters, as for example asystolic cross clamp time, total donor
warm ischemia time, the presence of hepatitis C virus, BAR and
MELD scores, donor age, and sex of the recipient (Table 1). Of note,
although constitutional variations in surgical technique, preservation
solution, and also time periods remained between centers, we would
like to emphasize that, despite all center-related differences, outcome
for DBD liver grafts are identical in Zurich, Rotterdam, and Bir-
mingham, as for example duration of transplant procedure (5.8 vs 6.2
vs 5 hours), intensive care unit (3 vs 4 vs 4 days) and hospital stay
(18.5 vs 18 vs 11 days), and also 1-year graft survival (93% vs 90% vs
90%). We assume therefore that HOPE significantly contributes to
the observed effect of decreased injury in HOPE-treated DCD livers
in contrast to unperfused DCD livers.
An appealing feature of the HOPE technique is its easy
application after conventional cold flush and organ transport (endi-
schemic perfusion) obviating the need for the cumbersome transport
of perfusion equipment. In contrast to the concept of normothermic
perfusion strategies, which intend to avoid any cold storage periods
by upfront delivering oxygenated blood under physiologic con-
ditions, the HOPE technique reversibly suppresses mitochondrial
oxidative metabolism after cold preservation decreasing the mito-
chondrial release of reactive oxygen species upon reperfusion with
several-fold deactivation of numerous intracellular and extracellular
pathways, including the host inflammatory response.31 It seems that
concomitant perfusion of the hepatic artery, in addition to oxy-
genated perfusion through the portal vein, is unnecessary (data
not shown).
The results of this study highlight an incidence of intrahepatic
biliary complications in 22% of unperfused DCD liver recipients and
a 1-year graft survival <70%. These findings are consistent with
most previous reports,2,7,33–35 although some groups have reported
better outcome.3,12,24,36,37 More important, those later studies have
focused on highly selected donor population, not qualifying as
extended DCD, that is, short donor asystolic warm ischemia time
(5–10 minutes), and donor age50 years24,36 or even40 years.3,37
In fact, almost no centers currently implant DCD livers with periods
of asystolic donor warm ischemia >20 minutes or donor age >60
years. A recent study from the Netherlands reported on 97 DCD liver
recipients with a median asystolic donor warm ischemia of 17
minutes and a donor age of 44 years. The incidence of nonanasto-
motic biliary strictures cumulated in this analysis to 31%,38 with a
strong correlation between the degree of initial reperfusion injury
(peak ALT) and subsequent biliary injury. This observation under-
lines the importance of the initial ischemia-reperfusion injury before
implantation, which, for example, can be prevented by machine
perfusion techniques.
In conclusion, this study provides strong evidence that apply-
ing HOPE protects extended DCD livers from initial reperfusion
injury leading to better graft function and the prevention of intra-
hepatic biliary complications. HOPE may therefore offer optimiz-
ation of liver grafts before implantation by a simple and practical
perfusion technique with a high impact on enlarging the donor pool.
To further test the HOPE strategy, we have initiated a multicentric
phase III RCT in DBD liver transplantation, which may establish the
protective effects of machine perfusion in liver transplantation.
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DISCUSSANTS
A. Pinna (Bologna, Italy):
The study performed by the group from Professor Clavien
shows that extracorporeal perfusion with oxygenated hypothermic
solution reduces graft injury in DCD liver grafts compared to static
cold preservation. The decrease of the postreperfusion liver injury of
such treated grafts is dramatically evident with better graft survival at
1 year of the treated DCD liver grafts compared with the DCD liver
grafts not treated with the HOPE technique. The study, however,
raised several questions. First, a possible major limitation of the
study is the comparison made among transplants performed in
different centers at different time periods. Is this a concern in the
evaluation of the results? Second, can the authors better explain
whether the advantage of HOPE was due to the liver perfusion or
from the oxygenation of the perfusate? Third, do the authors think
that there is a difference according to the use of different solutions
among the 3 centers? Finally, can the authors clarify if they used or
not thrombolytic treatment of the liver grafts after retrieval in any
arm of the study? This is a well-conducted study full of HOPE for
the future.
Response From P. Dutkowski (Zurich, Switzerland):
Thank you Professor Pinna for your valuable comments and
questions. We agree that there are differences among the centers in
terms of the transplant technique, surgeons, preservation solutions,
and time periods. Despite that, outcome in the brain dead (DBD) liver
grafts, that is, control groups, was identical in Zurich, Rotterdam, and
Birmingham. Therefore, we assume that constitutional variations are
rather unlikely to have a major effect on graft outcome. Centers have
differences in terms of warm ischemia periods and biliary compli-
cations, for example, the rate of intrahepatic cholangiopathy is low in
Birmingham with 85% 1-year graft survival, but asystolic warm
ischemia time is generally short. Although a center comparison was
not the aim of this study, we opted to search for best matches in terms
of key confounders including warm ischemia periods. Based on this
analysis, we believe that HOPE significantly contributes to the
observed effects of decreased injury in HOPE-treated DCD livers
in contrast to unperfused DCD livers.
Next, we are convinced that the effects of HOPE depends on
the oxygenation of the perfusate, as demonstrated in recent exper-
imental studies in pig livers published recently by our group.
Furthermore, experimental studies with gaseous oxygenation without
any perfusate also showed a protective effect. Based on this, we
currently regard hyperbaric oxygen as the key compound in the
HOPE procedure. Finally, no fibrinolytic agents have been used in
this study in DCD patients.
T. van Gulik (Amsterdam, The Netherlands):
It is very important that you could show that, contrarily to
many beliefs, rescue of the biliary system does not need separate
perfusion of the hepatic artery. You succeeded to obtain sufficiently
high oxygen saturation by perfusion of the portal vein only. We can
now get rid of the technical problems of dual perfusion including the
hepatic artery. There are also interesting reports showing that sub-
normothermic perfusion of the liver is also protective probably
through the same pathway. If you combine hyperoxygenation with
slightly higher temperature than hypothermic, then the effects might
even be greater although difficult to show because your results are
already very impressive.
Dutkowski et al Annals of Surgery  Volume 262, Number 5, November 2015
770 | www.annalsofsurgery.com  2015 Wolters Kluwer Health, Inc. All rights reserved.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Response From P. Dutkowski (Zurich, Switzerland):
The ideal temperature for machine liver perfusion remains
currently unclear. It might be 108C, 158C, or even 208C, as you
suggested. We believe, however, that the protective key mechanism
relies on a reversible downregulation of mitochondrial electron
transfer, which best occurs at low temperatures. Future studies are
needed to unravel this issue.
R. Adam (Paris, France):
We want to go a step forward and see now what may happen
using HOPE for DBD donors. This is the case in my country because
we still have few DCD donors. I know that you are now proposing
a prospective randomized study and we will be very keen to
participate in it. Do you think that we should be open to this
study to all liver grafts, including those without any risk factor,
or should we reserve our focus to risky grafts in a way to have a
higher chance to demonstrate differences between HOPE and no
HOPE treatment?
Response From P. Dutkowski (Zurich, Switzerland):
The benefit of HOPE or other machine perfusion techniques is
probably higher in preinjured liver grafts. Therefore, inclusion of too
many standard livers in the randomized trial may show less beneficial
effects. As the number of accepted and implanted extended criteria
liver grafts is increasing everywhere, we would, however, keep at the
moment the trial design omitting any selection.
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